Lotus Pharmaceutical Co., Ltd. (1795.TW)
TWD 260.5
(-1.14%)
TWD 260.5
(-1.14%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 9.81 Billion TWD | 41.52% |
| 2022 | 6.93 Billion TWD | 45.01% |
| 2021 | 4.78 Billion TWD | 19.99% |
| 2020 | 3.98 Billion TWD | 4.66% |
| 2019 | 3.8 Billion TWD | 263.22% |
| 2018 | 1.04 Billion TWD | -70.2% |
| 2017 | 3.51 Billion TWD | 20.92% |
| 2016 | 2.9 Billion TWD | -2.22% |
| 2015 | 2.97 Billion TWD | -4.2% |
| 2014 | 3.1 Billion TWD | 583.66% |
| 2013 | -642.24 Million TWD | -857.43% |
| 2012 | -67.08 Million TWD | 63.19% |
| 2011 | -182.21 Million TWD | -21.62% |
| 2010 | -149.82 Million TWD | -182.93% |
| 2009 | -52.95 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 7.81 Billion TWD | -8.29% |
| 2024 Q1 | 8.51 Billion TWD | -13.2% |
| 2023 Q2 | 9.32 Billion TWD | 2.35% |
| 2023 FY | 9.81 Billion TWD | 41.52% |
| 2023 Q1 | 9.11 Billion TWD | 31.41% |
| 2023 Q3 | 9.73 Billion TWD | 4.33% |
| 2023 Q4 | 9.81 Billion TWD | 0.86% |
| 2022 Q4 | 6.93 Billion TWD | 3.31% |
| 2022 Q3 | 6.71 Billion TWD | 11.09% |
| 2022 Q2 | 6.04 Billion TWD | -3.44% |
| 2022 FY | 6.93 Billion TWD | 45.01% |
| 2022 Q1 | 6.25 Billion TWD | 30.85% |
| 2021 Q3 | 4.72 Billion TWD | -13.0% |
| 2021 Q1 | 4.95 Billion TWD | 24.37% |
| 2021 FY | 4.78 Billion TWD | 19.99% |
| 2021 Q2 | 5.43 Billion TWD | 9.56% |
| 2021 Q4 | 4.78 Billion TWD | 1.21% |
| 2020 Q2 | 4.59 Billion TWD | 41.51% |
| 2020 Q1 | 3.24 Billion TWD | -14.7% |
| 2020 FY | 3.98 Billion TWD | 4.66% |
| 2020 Q4 | 3.98 Billion TWD | -13.09% |
| 2020 Q3 | 4.58 Billion TWD | -0.23% |
| 2019 FY | 3.8 Billion TWD | 263.22% |
| 2019 Q4 | 3.8 Billion TWD | 1.36% |
| 2019 Q3 | 3.75 Billion TWD | 43.11% |
| 2019 Q1 | 2.74 Billion TWD | 161.62% |
| 2019 Q2 | 2.62 Billion TWD | -4.28% |
| 2018 Q2 | 1.24 Billion TWD | -57.88% |
| 2018 Q3 | 1.11 Billion TWD | -10.74% |
| 2018 FY | 1.04 Billion TWD | -70.2% |
| 2018 Q1 | 2.96 Billion TWD | -15.71% |
| 2018 Q4 | 1.04 Billion TWD | -5.98% |
| 2017 Q3 | 2.58 Billion TWD | -0.25% |
| 2017 Q4 | 3.51 Billion TWD | 36.2% |
| 2017 FY | 3.51 Billion TWD | 20.92% |
| 2017 Q1 | 2.44 Billion TWD | -15.89% |
| 2017 Q2 | 2.58 Billion TWD | 5.81% |
| 2016 Q4 | 2.9 Billion TWD | 19.76% |
| 2016 FY | 2.9 Billion TWD | -2.22% |
| 2016 Q3 | 2.42 Billion TWD | -7.82% |
| 2016 Q2 | 2.63 Billion TWD | -3.66% |
| 2016 Q1 | 2.73 Billion TWD | -8.07% |
| 2015 Q1 | 3.07 Billion TWD | -0.85% |
| 2015 Q2 | 2.92 Billion TWD | -5.07% |
| 2015 Q3 | 3.24 Billion TWD | 10.99% |
| 2015 Q4 | 2.97 Billion TWD | -8.3% |
| 2015 FY | 2.97 Billion TWD | -4.2% |
| 2014 Q1 | -521.71 Million TWD | 18.77% |
| 2014 Q3 | -818.63 Million TWD | -115.22% |
| 2014 Q2 | -380.36 Million TWD | 27.09% |
| 2014 FY | 3.1 Billion TWD | 583.66% |
| 2014 Q4 | 3.1 Billion TWD | 479.44% |
| 2013 Q2 | 4.74 Million TWD | 135.3% |
| 2013 Q3 | 43.03 Million TWD | 806.23% |
| 2013 Q4 | -642.24 Million TWD | -1592.31% |
| 2013 FY | -642.24 Million TWD | -857.43% |
| 2013 Q1 | -13.45 Million TWD | 79.94% |
| 2012 FY | -67.08 Million TWD | 63.19% |
| 2012 Q1 | -133.87 Million TWD | 26.53% |
| 2012 Q2 | -7.3 Million TWD | 94.54% |
| 2012 Q3 | 196.5 Million TWD | 2789.26% |
| 2012 Q4 | -67.08 Million TWD | -134.14% |
| 2011 Q2 | 7.13 Million TWD | 106.42% |
| 2011 Q1 | -111.07 Million TWD | 25.87% |
| 2011 FY | -182.21 Million TWD | -21.62% |
| 2011 Q4 | -182.21 Million TWD | -382.31% |
| 2011 Q3 | 64.54 Million TWD | 804.6% |
| 2010 Q4 | -149.82 Million TWD | 0.0% |
| 2010 FY | -149.82 Million TWD | -182.93% |
| 2009 FY | -52.95 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Grape King Bio Ltd | -4.62 Billion TWD | 312.157% |
| Standard Chem & Pharm CO., LTD. | -954.74 Million TWD | 1127.911% |
| Maywufa Company Ltd. | 264.18 Million TWD | -3614.787% |
| ScinoPharm Taiwan, Ltd. | -3.32 Billion TWD | 395.562% |
| LIWANLI Innovation Co., Ltd. | -244.02 Million TWD | 4121.715% |
| YungShin Global Holding Corporation | -247.5 Million TWD | 4065.2% |
| PhytoHealth Corporation | -34.64 Million TWD | 28430.328% |
| SCI Pharmtech, Inc. | 100.41 Million TWD | -9673.155% |
| Formosa Laboratories, Inc. | 2.53 Billion TWD | -286.619% |
| PharmaEssentia Corporation | -18.46 Billion TWD | 153.146% |
| Bora Pharmaceuticals Co., LTD. | 1.95 Billion TWD | -401.592% |